Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb

This article was originally published in The Tan Sheet

Executive Summary

Restructuring and realignment plan announced Jan. 4 includes a reduction of employee levels by "approximately 5,000" worldwide "during the next two years." The company noted that "four Bristol- Myers Squibb core businesses" -- consumer products, nutritionals, pharmaceuticals and medical devices -- and "headquarters staff will be affected." Most of the staff cuts will be in BMS' prescription Pharmaceutical Group, which will be reorganized into 12 regional business units in the U.S. Eleven business units will be formed in Europe covering all BMS product categories
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel